India · Updated November 2026 · Revised Schedule M design basis
Pharma Plant Setup Cost Calculator
Estimate what a pharmaceutical manufacturing plant costs to build, expand or upgrade in India — dosage form by dosage form, at your own capacity, on a Revised Schedule M, WHO-GMP, EU-GMP or US-market-oriented design basis. You get a low, likely and high project cost, then the timeline, manpower, running cost and finance view that go with it.
Project Cost Estimator
Laafon project-rate basis · INR · indicative 2026What are you building, and where?
A new plant, a new block on an existing site and an upgrade of a running plant are three different projects with three different cost shapes. Pick the one that matches yours.
Which dosage forms, and at what capacity?
Each dosage form brings its own machinery, classified area and HVAC load. Capacity scales cost on a curve rather than a straight multiple, because doubling output enlarges the machines and rooms but not the whole plant.
Enter capacity as total output per day. With two or three shifts the same daily output needs a smaller line, so machinery cost falls while production manpower rises.
Sterile dosage form selected. A water-for-injection and pure steam system is added automatically, sterile-grade HVAC rates apply, and the QC laboratory gains area and microbiology instruments.
Dedicated or segregated block selected. Revised Schedule M requires separate, dedicated and self-contained facilities for penicillins and cephalosporins, and for sex hormones, steroids and cytotoxic substances. EU-GMP and PIC/S decide dedication through a documented, toxicology-based risk assessment, but most plants supplying these products still build self-contained blocks, so they are priced that way here, with their own air handling and exhaust treatment.
Nutraceutical and Ayurvedic lines are licensed under different laws from allopathic drugs. The cost model prices the building and equipment the same way; the licence checklist in your report changes to match.
Which standard is the plant being built to?
For export grades this moves the number more than capacity does. Equipment grade, HVAC specification, segregation area, validation scope and laboratory instrumentation all step up together with the target market.
Leave empty for a domestic-only plant.
After calculating you will see the same plant priced under all four standards side by side — useful when deciding whether an export-grade build justifies its premium.
Facility, machinery and utilities
Leave these on their defaults for a first estimate. Change them when you know more — every option is priced separately so you can see what it does to the total.
Building and machinery
Utilities
How is the project funded?
These drive the EMI and payback figures in your report. They do not change the project cost itself.
Cost allowances
Defaults follow common Detailed Project Report practice. Raise contingency to 8-10 per cent if your layout and equipment list are still moving.
Government schemes — do you expect to qualify?
These are flags for your report, not subsidy calculations. No scheme amount is deducted from the estimate, because eligibility and open windows have to be confirmed for your unit.
How will the plant earn?
The business model sets the default selling value per unit and the margin kept after materials. Both are editable — put in your own figures and the break-even and payback in your report follow them.
Share of installed capacity actually sold. New plants rarely start above 40 per cent.
Average selling value per unit
Ex-factory value per tablet, bottle or vial for your product mix. The defaults are deliberately conservative — set at today’s lowest average rates — so enter your own values if your portfolio sells higher.
Estimated project cost
Select a dosage form
Indicative planning estimate at 2026 prices, excluding GST. Not a quotation, benchmark, or regulatory or financial advice. Actual costs vary with location, vendor, design, product, taxes and approvals.
Get a detailed project report and plant layout from Laafon
Unlocks instantly on this page · reviewed by our team
Your detailed report is unlocked below. Use the print button there to save it as a PDF.
Please enter your name and a phone number of at least seven digits.
We use these details only to send your report and answer questions about it. Your plan inputs are kept in this browser so you can return to them; your name and contact details are not. Reset clears the plan.
Where the money goes
Each bar is a cost head at the likely estimate. The line-by-line detail is below the chart.
Cost breakdown — tap any line for detail
Same plant, four standards
Identical dosage forms and capacities, priced under each compliance grade, excluding land.
Lower-capital routes to the same market
Project timeline
Built-up area and suggested layout zones
| Zone | What it holds | Area |
|---|
Manpower and monthly salary bill
Headcount at the selected number of shifts. Salaries are average monthly cost to company by department; contract labour and security are not counted.
| Department | People | Per month |
|---|
Monthly running cost
Fixed cost of keeping the plant running, before raw and packing materials.
| Head | Per month |
|---|
Financial view
Compare two scenarios
Scenario A is your current plan. Choose what Scenario B changes.
| Measure | A · current | B | Difference |
|---|
Licences and approvals checklist
Filtered to your inputs. Requirements, forms and fees differ by state and change often — treat this as a planning list and confirm each item with the authority named.
How to read this estimate. Figures are built bottom-up from component rates — machinery per dosage form, HVAC and cleanroom finish per sq ft of classified area, utilities sized on connected load, and laboratory, validation and pre-operative allowances per compliance grade. Every rate is listed in the methodology section below. Equipment is priced at domestic Indian OEM levels, 2026, excluding GST, unless you choose a higher machinery level. The low and high figures are the planning band for the chosen standard and project type, not a guarantee of either. These are indicative planning figures, not a quotation. Actual costs move with vendor selection, imported versus domestic equipment, site conditions, statutory fees and procurement timing. Use this to size funding and compare configurations, then commission a Detailed Project Report before committing capital.
How much does it cost to set up a pharma plant in India?
On this model, a single tablet section at 5 lakh tablets per day, built to Revised Schedule M, comes to roughly ₹10 crore excluding land on about 10,500 sq ft built-up, including QC laboratory, utilities, contingency and working capital margin. A three-section WHO-GMP unit — tablets, capsules and liquid orals — lands near ₹23 crore. A sterile liquid-vial injectable facility at EU-GMP is closer to ₹27 crore. Land typically adds under 10 per cent. For export grades the standard moves the number more than capacity does: the same tablets-plus-capsules plant prices at about ₹14.6 crore under Schedule M and ₹24.4 crore under EU-GMP.
Which route actually fits you?
Two questions. The answer tells you whether to build, upgrade or buy — and what to do next.
1. What do you have today?
2. Which market are you supplying?
Choose an answer to both questions
Your route depends on what you already own and where the product is going. Pick one option in each row above.
Understanding the numbers
What actually drives pharma plant cost in India
Most published estimates fail because they treat compliance grade as a footnote. In practice it outweighs capacity, location and even dosage form.
Where Revised Schedule M stands, and what it means for a new build
Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023[1]. G.S.R. 127(E), dated 11 February 2025, allowed eligible small and medium manufacturers with turnover below ₹250 crore to seek an extension until 31 December 2025 by submitting the required application and upgradation plan[2]. That window has closed, no further extension has been notified, and the rules are in the enforcement phase: in November 2025 the DCGI directed state and UT drug controllers to begin inspections immediately for units that had not sought an extension, with units holding extensions to be inspected from January 2026[9]. Confirm your own unit’s position with CDSCO and your State Licensing Authority.
For a new build the practical consequence is simpler than for an existing unit: Revised Schedule M is the Indian GMP text a new plant is designed and licensed against, so the domestic baseline in the calculator above assumes it. If you already operate a unit, choose “Upgrade an existing plant” in Step 01 for an order-of-magnitude retrofit allowance, and use the Revised Schedule M compliance dashboard to score readiness across the twelve areas inspectors look at. A retrofit figure from any calculator is only a placeholder until a gap assessment has been done on the actual plant.
Compliance standard is the dominant cost variable
The same plant — same dosage forms, same capacity, same state — costs roughly 60 to 100 per cent more when built to an EU-GMP or US-market-oriented basis than to Revised Schedule M. It is worth being precise about why, because the popular explanation, that export-grade machines cost many times more, overstates the equipment effect and understates everything around it.
What genuinely changes as you move from Revised Schedule M to WHO-GMP[3], then to EU-GMP[4] and a US-market-oriented design basis[6] is a stack of things that each carry capital cost: tighter cleanroom classification and therefore heavier HVAC and filtration; more instrumented and automated equipment with full material-of-construction documentation; electronic records and data integrity capability across every system that generates GMP data; a far larger qualification and validation programme; wider corridors and airlocks for segregation and personnel flow; and a QC laboratory carrying analytical instrumentation of a different order.
Sterile products carry an additional design layer. For sterile manufacture specifically, the EU GMP Annex 1 revision published on 25 August 2022 and in operation from 25 August 2023, with the lyophilisation provision at point 8.123 deferred to 25 August 2024, makes a documented contamination control strategy and barrier technology an explicit design expectation rather than a preference[5]. That applies to injectables, ophthalmics and other sterile dosage forms; it does not govern oral solids or liquid orals.
The calculator prices each of those effects separately rather than applying one blanket multiplier. Equipment carries a grade factor of 1.1 for WHO-GMP, 1.7 for EU-GMP and 2.0 for a US-oriented basis, reflecting a mix of export-grade domestic and imported machines with full documentation. Classified area grows by 5 to 25 per cent for segregation and airlocks. HVAC runs from about ₹1,300 per sq ft of classified area for a Schedule M oral solid block to ₹4,000 or more for sterile Grade B and C areas. Validation, laboratory and computerised-system allowances step up by grade. The full rate table is in the methodology section below. Treat the Schedule M and WHO-GMP figures as reasonably firm and the EU-GMP and US-oriented figures as indicative, with a wider band, because at that end the spread between two credible vendor lists is genuinely large.
One thing the US-oriented tier is not. Building to a US-market-oriented design basis is a design and capital decision only. It is not a certification, an accreditation, or any guarantee of USFDA approval — that depends on the marketing application, the outcome of facility inspection, and sustained compliance thereafter. The tier exists here so you can size the capital gap before deciding whether to pursue that route, not to imply the route is secured by spending the money.
Capacity matters less than most promoters expect
Doubling output does not double cost. The calculator scales machinery with the six-tenths rule used in process-plant cost estimation, so machinery rises about 50 per cent for a doubling, and classified area rises about 37 per cent. Because the QC laboratory, utility backbone and support buildings barely change, the whole project rises only about 25 to 30 per cent for a doubling of capacity — on this model, a 5 lakh tablets-per-day Schedule M unit moves from about ₹10.1 crore to ₹12.7 crore at 10 lakh per day.
Shifts work the other way. Capacity is entered as output per day, so ten lakh tablets a day on two shifts needs the same line as five lakh on one — the capital stays near ₹10.1 crore and the extra cost moves into production manpower and power. For a plant that will sell on thin conversion margins, that is usually the difference between a project that pays and one that does not.
The practical implication: if you are choosing between 5 lakh and 10 lakh tablets per day, the larger line is almost always better on cost per unit — provided the market absorbs the output. If it does not, the cheaper route to volume is usually someone else’s line, which is what third-party manufacturing exists for.
Dosage-form packages, not machine lists
Each dosage form carries three linked costs: machinery, its classified area, and the HVAC that serves that area. A tablet section at 5 lakh per day needs about 7,000 sq ft classified; capsules at the same output about 4,000; liquid orals around 7,000; dry syrup 3,000; ointments and creams 2,500; and sterile injectables about 5,000 sq ft with a far heavier machinery and HVAC load. Beta-lactam tablet sections match non-beta on machinery but carry 30 per cent more HVAC cost for dedicated air handling and exhaust filtration, because segregation of penicillins and cephalosporins is not negotiable under any of these standards.
Eight further packages cover soft gelatin capsules, external liquids, ophthalmic drops, large volume parenterals, a cephalosporin block, a hormone and cytotoxic containment block, nutraceuticals and Ayurvedic products. Their rates rest on fewer reference projects than the core eight, so each one widens the planning band by five percentage points. The package table in the methodology section lists every rate so you can test them against your own quotations.
Land is smaller than most promoters assume
Greenfield land requiring industrial conversion runs roughly ₹150 to ₹400 per sq ft across the main pharma states — Himachal Pradesh (Baddi, Solan, Una) and Uttarakhand (Haridwar, Roorkee) around ₹300, Gujarat lower, Haryana higher. Change of Land Use charges add roughly 5 per cent of land value, though the rate and the process are state-specific and should be confirmed with the local authority before it goes into a funding plan. A developed plot in a notified industrial area, pharma park or SEZ costs more per sq ft but needs no conversion; the calculator applies a multiplier to the state rate for those, and you should overwrite it with the allotment price you are actually quoted. On most projects land ends up under 10 per cent of total cost — about 7 per cent for a tablets-plus-capsules unit in Himachal Pradesh on this model — which is why optimising location for vendor access, effluent infrastructure and skilled manpower usually beats optimising for cheap land.
Worked examples
Calculated on the same model this page runs, at default settings and excluding land so they stay comparable:
| Configuration | Standard | Built-up | Cost excl. land |
|---|---|---|---|
| Tablets, non-beta — 5 lakh per day, Himachal Pradesh | Revised Schedule M | ~10,500 sq ft | ₹10.1 Cr |
| Tablets, capsules and liquid orals — reference capacities, Uttarakhand | WHO-GMP | ~25,500 sq ft | ₹23.3 Cr |
| Injectables, liquid vial — 1 lakh vials per day, Haryana | EU-GMP | ~10,000 sq ft | ₹26.6 Cr |
Scroll the table sideways on a phone
And the comparison that matters most — one plant, tablets plus capsules in Himachal Pradesh excluding land, across all four grades:
| Standard | Project cost | vs Schedule M | Typical market |
|---|---|---|---|
| Revised Schedule M | ₹14.6 Cr | baseline | Domestic India |
| WHO-GMP | ₹16.2 Cr | +11% | Africa, LatAm, CIS tenders |
| EU-GMP | ₹24.4 Cr | +68% | European regulated markets |
| US-market-oriented design basis | ₹28.1 Cr | +93% | United States |
Scroll the table sideways on a phone
The step from Schedule M to WHO-GMP is modest — largely HVAC specification, stability capacity and cleanroom finish, since the underlying GMP principles are closely aligned. The step to EU-GMP or a US-market-oriented basis is a different order of investment, and should be underwritten by a committed export order book rather than optimism. Those two rows carry a wider uncertainty band than the first two, and the calculator reflects that in its low and high figures.
Timeline, manpower and running cost
The detailed report adds three things a capital figure alone cannot tell you. The timeline runs seven overlapping phases from land and approvals to commercial production. For the single tablet section above, with land still to be bought, the model gives about 18 months; sterile and export-grade plants run longer because design, equipment delivery and qualification each take more time. Statutory approvals do not run to a fixed clock, so the licensing phase is the one most likely to move.
Manpower is built from a production crew per dosage form per shift, plus QA, QC, engineering, stores and administration that grow with the number of dosage forms and the compliance grade. The same tablet section comes to about 43 people on one shift. Monthly running cost adds power on the connected load, maintenance, consumables and overheads to that salary bill. It deliberately excludes raw and packing materials, which sit inside the margin you enter in Step 06.
What the finance view assumes
The finance view is a first-pass screen, not a project appraisal. It takes your daily capacity, 300 working days a year and the utilisation you choose, multiplies by an average ex-factory value per unit, keeps the margin you enter after materials, and subtracts the monthly running cost. From that it reports EMI on a standard reducing-balance term loan, the utilisation at which the plant covers its running cost and its EMI, a simple pre-tax return on project cost, and payback. Depreciation, tax, interest during construction, ramp-up losses and GST on capital goods are outside it. The default selling values are deliberately conservative, set at today’s lowest average rates, so the screen errs on the cautious side until you enter your own.
Expect it to be blunt. A single-shift plant selling third-party manufacturing on contract margins will often cover its running cost but struggle to service its loan until utilisation is high — that is a real feature of the business, and it is the reason contract plants run two or three shifts. If your result looks poor, the report tells you what it would take to clear the EMI; change shifts, product value and margin before changing the plant, and compare the lower-capital routes the calculator lists: a loan licence, third-party manufacturing, a unit on rent, or an existing licensed plant.
Government schemes: what the yes or no flags mean
The calculator records whether you expect to qualify for support and carries that into your report. It does not deduct any subsidy from the estimate, for a simple reason: none of these can be assumed until eligibility and an open application window are confirmed for your unit.
The Revamped Pharmaceuticals Technology Upgradation Assistance Scheme was announced by the Department of Pharmaceuticals in March 2024 to support existing units upgrading to Revised Schedule M and WHO-GMP, with assistance on a reimbursement basis[10]. It is an upgrade scheme, so it bears on the upgrade project type rather than a greenfield build. Its clauses were modified again on 21 March 2026[11], and in August 2026 the government told Parliament that pending applications from Himachal Pradesh units were on hold under a temporary restriction, awaiting an expenditure committee decision[13]. Check with the Department whether applications are being processed before counting on it. The Production Linked Incentive schemes selected their participants through application rounds; the bulk-drug scheme has reopened only for specific products[12], and a new formulation plant should not budget for PLI unless a fresh round is notified. The central Industrial Development Scheme, 2017 for Himachal Pradesh and Uttarakhand closed to new units in March 2022, so hill-state sites should be costed on state industrial policy benefits alone, confirmed in writing.
What sits outside this estimate
The project cost covers capital cost to commissioning plus a working capital margin. The report adds indicative EMI, running cost, break-even and payback. Neither includes interest during construction in the project cost, GST on capital goods, API and excipient procurement, product development, dossier and registration costs, or tax. For funding structure, subsidies and payback expectations in more depth, read our companion guide to pharma manufacturing plant investment in India, which covers capex bands, the PLI scheme and financing. And if buying an existing licensed unit is faster than building one, compare plants listed for sale and rent before you commit to a greenfield timeline — each listing states how far its details have been checked.
Methodology and the rates this calculator uses
Each estimate is built bottom-up. Machinery is priced per dosage form at a reference capacity using domestic Indian OEM equipment at 2026 prices, excluding GST, and scaled to your per-shift capacity with a 0.6 exponent. HVAC and cleanroom finish are priced per sq ft of classified area; the building shell at ₹1,900 per sq ft for process blocks, ₹1,600 for the warehouse, ₹1,800 for utility and admin and ₹2,400 for the QC laboratory. Electrical infrastructure including transformer and DG set is sized on an estimated connected load at about ₹22,000 per kVA. Purified water, WFI, steam, compressed air, effluent treatment and fire-fighting are added as sized allowances. The resulting cost-head split was cross-checked against published capex breakdowns for Indian oral-dosage and injectable plants[7][8]. Expansion and upgrade projects apply reduction factors to the same heads, and carry a wider band because the real figure depends on what is already on site. Grade-dependent rates are below; they are generated from the same data the calculator runs on, so the two cannot drift apart.
| Rate | Schedule M | WHO-GMP | EU-GMP | US-oriented |
|---|
Scroll the table sideways on a phone
Dosage-form packages at reference capacity and Indian standard machinery, before the grade factor:
| Dosage form | Reference capacity per shift | Machinery | Classified area | Crew per shift | Default value per unit |
|---|
Scroll the table sideways on a phone
References
- 1. Ministry of Health and Family Welfare, Government of India. Drugs (Amendment) Rules, 2023 — G.S.R. 922(E), Revised Schedule M. New Delhi: Gazette of India; 28 December 2023. Available from: https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/. Accessed November 2026.
- 2. Ministry of Health and Family Welfare, Government of India. Drugs (Amendment) Rules, 2025 — G.S.R. 127(E), extension of Revised Schedule M timeline for manufacturers with turnover up to ₹250 crore. New Delhi: Gazette of India; 11 February 2025. Available from: https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/. Accessed November 2026.
- 3. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series 986, Annex 2. Geneva: WHO; 2014. Available from: https://www.who.int/publications/m/item/trs986-annex2. Accessed August 2026.
- 4. European Commission. EudraLex Volume 4 — Good Manufacturing Practice (GMP) guidelines for medicinal products for human and veterinary use. Brussels: European Commission. Available from: https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en. Accessed August 2026.
- 5. European Commission. EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. Published 25 August 2022; in operation 25 August 2023, point 8.123 from 25 August 2024. Available from: https://health.ec.europa.eu/latest-updates/revision-manufacture-sterile-medicinal-products-2022-08-25_en. Accessed August 2026.
- 6. US Food and Drug Administration. Title 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals. Washington DC: Electronic Code of Federal Regulations. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211. Accessed August 2026.
- 7. IMARC Group. Pharmaceutical manufacturing plant setup in India: cost, process flow, machinery, DPR and financial guide 2026. Available from: https://www.imarcgroup.com/insight/pharmaceutical-manufacturing-plant-setup-cost-india. Accessed October 2026.
- 8. IMARC Group. Generic injectables plant setup cost in India: manufacturing process flow, machinery, DPR and financial model 2026. Available from: https://www.imarcgroup.com/insight/generic-injectables-manufacturing-plant-setup-cost-india. Accessed October 2026.
- 9. KNN India. CDSCO orders immediate inspections to enforce revised Schedule M GMP rules. New Delhi; 8 November 2025. Available from: https://knnindia.co.in/news/newsdetails/sectors/others/cdsco-orders-immediate-inspections-to-enforce-revised-schedule-m-gmp-rules. Accessed October 2026.
- 10. Press Information Bureau, Government of India. Department of Pharmaceuticals announces the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme. New Delhi; March 2024. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2013379. Accessed November 2026.
- 11. Department of Pharmaceuticals, Government of India. Scheme for Strengthening of Pharmaceuticals Industry (SPI): notification of the modification in the clauses under sub-scheme RPTUAS, dated 21 March 2026. New Delhi. Available from: https://pharma-dept.gov.in/schemes/scheme-strengthening-pharmaceuticals-industry-spi. Accessed November 2026.
- 12. Medical Dialogues. Meropenem, Ritonavir back in focus as DoP reopens PLI application window till March 12. New Delhi; 1 March 2026. Available from: https://medicaldialogues.in/news/industry/pharma/meropenem-ritonavir-back-in-focus-as-dop-reopens-pli-application-window-till-march-12-165636. Accessed November 2026.
- 13. Indian Pharma Post. Centre sanctions over Rs. 84 crore for pharma infrastructure in Himachal Pradesh. New Delhi; 4 August 2026. Available from: https://www.indianpharmapost.com/news/centre-sanctions-over-rs-84-crore-for-pharma-infrastructure-in-himachal-pradesh-21236. Accessed November 2026.
Common questions
Pharma plant cost, answered
On this model a single tablet section at 5 lakh tablets per day built to Revised Schedule M works out to roughly ₹10 crore excluding land, on about 10,500 sq ft built-up, including QC laboratory, utilities, contingency and working capital margin. A three-section WHO-GMP unit lands near ₹23 crore, and a sterile liquid-vial injectable facility at EU-GMP around ₹27 crore. Land typically adds under 10 per cent of the total. These are indicative planning figures built from the component rates published on this page, not quotations.
Not because of paperwork alone. Moving to EU-GMP or a US-market-oriented design basis changes tighter cleanroom classification and therefore HVAC and filtration load, the level of instrumentation and automation on each machine, electronic records and data integrity capability across every GMP system, the size of the qualification and validation programme, the corridor and airlock area needed for segregation, and the analytical instrumentation carried by the QC laboratory. Each of those is a capital line, and they compound. Note that building to such a basis is a design decision, not a certification or a guarantee of approval in any market.
No. Machinery rises about 50 per cent for a doubling of output and classified area about 37 per cent, while the QC laboratory, utility backbone and support buildings barely change. The whole project therefore rises roughly 25 to 30 per cent, which usually makes the larger line better on cost per unit provided demand supports it. Running a second shift on the same line raises output without that capital at all. The calculator applies this as a scaling curve on per-shift capacity rather than straight multiplication.
Revised Schedule M was notified through G.S.R. 922(E) dated 28 December 2023. G.S.R. 127(E), dated 11 February 2025, allowed eligible small and medium manufacturers with turnover below ₹250 crore to seek an extension until 31 December 2025 by submitting the required application and upgradation plan. That window has closed and state inspections are under way, so the rules are in their enforcement phase. Confirm your own unit’s position with CDSCO and your State Licensing Authority. For costing a new plant the effect is straightforward: Revised Schedule M is the Indian GMP text the design is prepared against, and it is the domestic baseline used in this calculator.
Land area follows built-up area divided by permissible ground coverage, typically 45 per cent, so a 10,500 sq ft plant needs roughly 23,000 sq ft of land. You choose whether it is to be bought, already owned or leased. Rates default to indicative greenfield land requiring industrial conversion, with a 5 per cent allowance for Change of Land Use charges — a figure that varies by state and district and should be confirmed locally. Developed industrial plots carry a higher rate and no conversion charge.
Capital cost to commissioning and a working capital margin are included, and the detailed report adds indicative EMI, monthly running cost, break-even and payback. Interest during construction, GST on capital goods, API and excipient procurement, product development and registration costs, depreciation and tax are not. Those belong in a Detailed Project Report prepared against your specific product portfolio and market, with firm vendor quotations behind every equipment line.
For a single oral solid section built to Revised Schedule M, with land still to be bought, this model gives about 18 months from land and approvals to commercial production: design overlaps with approvals, equipment is ordered while civil work is still in progress, and qualification overlaps with the licence application. Sterile and export-grade plants take longer because design, equipment delivery and validation each stretch. Owning the land already, or upgrading an existing licensed unit, shortens it. Statutory approvals do not run to a fixed clock, so treat the licensing phase as the least certain.
Often, but not automatically. A running licensed unit saves most of the construction and licensing timeline and is frequently offered below the cost of building the same scope new. Against that, an older unit may need capital to meet Revised Schedule M, and its asking price reflects licences, product permissions and turnover as well as bricks and machines. The sound comparison is asking price plus the cost of closing the compliance gap, set against a new build and the months it takes. The calculator shows that comparison as a planning range; a due diligence review of the specific plant replaces it with a real number.
Your plan inputs are saved in your own browser so that you can close the page and return to the same plan; your name and contact details are not stored there, and the Reset button clears the plan. Nothing is sent to Laafon until you submit your contact details to unlock the detailed report or choose to send the project on WhatsApp. When you do, we receive your details and a summary of the plan you entered, and use them only to send your report and answer questions about it.
Related on Laafon
The narrative companion to this tool — capex bands, cost-component percentages, PLI and state subsidies, and how projects are financed.
GMP concept and layout design, room classification, flow and pressure cascade logic — the step that fixes most of the cost before civil work starts.
A two-minute self-assessment scoring your existing unit across twelve inspection focus areas, with a status and applicability tracker.
Listings of licensed units, each marked with how far its details have been checked. Worth comparing against a greenfield build before you commit to the construction timeline.
Licensed facilities available on rent, for promoters who want their own manufacturing address without construction capital.
If you need product in the market before a plant can be commissioned, this is the interim route and what it involves.
Manufacturing on an existing approved line instead of building your own — usually the cheaper route to volume below a certain scale.
Darshan Singh, 23+ years in pharmaceutical quality control, quality assurance and drug regulatory affairs.
23+ years in pharmaceutical QA, QC and regulatory affairs
Get a detailed project report and plant layout from Laafon
GMP layout and room classification, equipment specification, a fundable cost basis and the licensing pathway for your chosen state.
Disclaimer. This page is technical and educational content for pharmaceutical professionals. It is not medical, legal, financial or investment advice, and it is not a quotation. Cost, timeline, manpower and finance figures are indicative planning estimates at 2026 prices, built from the rates published on this page, and will differ from any specific vendor offer or bank appraisal. Actual costs vary by location, vendor and design. Indian statutory instruments, gazette notifications, government schemes, state Change of Land Use rules and pharmacopoeial texts change frequently — verify the current position with CDSCO, your State Licensing Authority, the Department of Pharmaceuticals and the relevant primary source before relying on anything here for a licensing or investment decision.
